These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 16859519)

  • 21. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of anti-cyclic citrullinated peptides antibodies in comparison with rheumatoid factor for rheumatoid arthritis diagnosis].
    Dubrous P; Gardet V; Hugard L
    Pathol Biol (Paris); 2005 Mar; 53(2):63-7. PubMed ID: 15708648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis.
    Besada E; Nikolaisen C; Nossent H
    Clin Exp Rheumatol; 2011; 29(1):85-8. PubMed ID: 21269572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic value of serum anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis].
    Yang CL; Zhou YR; Zhou F; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1277-9. PubMed ID: 17715048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
    Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
    Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
    Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
    Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis.
    Hill JA; Al-Bishri J; Gladman DD; Cairns E; Bell DA
    J Rheumatol; 2006 Nov; 33(11):2115-9. PubMed ID: 16924693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnostic performance of anti-cyclic citrullinated antibodies and IgM rheumatoid factor in rheumatoid arthritis].
    Lemos A; Ramos MP; Furtado MJ; Carvalho C; Santos MJ; Silva JC; Ventura H
    Acta Reumatol Port; 2007; 32(4):345-9. PubMed ID: 18159201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis.
    Grootenboer-Mignot S; Nicaise-Roland P; Delaunay C; Meyer O; Chollet-Martin S; Labarre C
    Scand J Rheumatol; 2004; 33(4):218-20. PubMed ID: 15370715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis.
    Lutteri L; Malaise M; Chapelle JP
    Clin Chim Acta; 2007; 386(1-2):76-81. PubMed ID: 17826752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis.
    Al-Jarallah K; Shehab D; Al-Attiyah R; Al-Azmi W; Al-Fadli A; Zafar Haider M; Panaccione R; Ghosh S
    Inflamm Bowel Dis; 2012 Sep; 18(9):1655-62. PubMed ID: 22114016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    Rheumatology (Oxford); 2008 Oct; 47(10):1489-92. PubMed ID: 18703528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis.
    Saraux A; Berthelot JM; Devauchelle V; Bendaoud B; Chalès G; Le Henaff C; Thorel JB; Hoang S; Jousse S; Baron D; Le Goff P; Youinou P
    J Rheumatol; 2003 Dec; 30(12):2535-9. PubMed ID: 14719190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies.
    Tanaka R; Takemura M; Sato M; Yamada Y; Nakagawa T; Horibe T; Hoshi M; Otaki H; Ito H; Seishima M; Shimizu K
    Clin Chim Acta; 2010 Jan; 411(1-2):22-5. PubMed ID: 19818336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis.
    Nikolaisen C; Rekvig OP; Nossent HC
    Scand J Rheumatol; 2007; 36(2):97-100. PubMed ID: 17476614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.